Fullerene nano-material for preventing and/or treating aplastic anemia and use thereof

Abstract

The invention discloses a fullerene nano-material for preventing and / or treating aplastic anemia and a use thereof. The use of the fullerene nano-material comprises 1, improving a leukocyte generation amount, 2, improving an erythrocyte generation amount, 3, improving a hemoglobin generation amount, 4, improving a platelet generation amount, 5, improving a hematocrit value, 6, improving a mean corpuscular volume, 7, improving mean corpuscular hemoglobin content or 8, improving a mean corpuscular hemoglobin concentration. The fullerene and / or metallofullerene nanometer material can be prepared through a simple and fast method, has good biocompatibility, has no toxic or side effects on organisms and can be used for related hemopoietic tissue through blood circulation. The fullerene and / or metallofullerene nanometer material has a certain protection and / or restoration effect on anaemia and related diseases and has obvious anaemia-related index recovery effects. The fullerene and / or metallofullerene nanometer material has stable properties and can protect and / or repair cells, blood and marrow.

Description

technical field [0001] The invention relates to a fullerene nanometer material for preventing and / or treating aplastic anemia and an application thereof, belonging to the field of biomedicine. Background technique [0002] According to the statistics of the World Health Organization, there are about 3 billion people with varying degrees of anemia in the world, and tens of millions of people die every year due to various diseases caused by anemia. In addition, the population probability of suffering from anemia in my country is higher than that of Western countries. Among the people suffering from anemia, women are significantly higher than men, and the elderly and children are higher than young and middle-aged people. About 30% to 40% of infants and young children suffer from anemia, and pregnant women up to 48%. Anemia is one of the most important diseases that threaten human health in the world and in our country. [0003] The so-called anemia means that the total amount ...

AI Technical Summary

Problems solved by technology

⑤Hemorrhagic anemia caused by chronic blood loss caused by long-term hemoptysis and loss of appetite, insufficient intake, resulting in malnutrition and anemia caused by tumor growth and consumption of nutrients in the body

Elimination of the cause is the key to the treatment of anemia, but it also needs to be treated in combination with other methods; general therapy mainly relieves symptoms through proper care, infection prevention, and attention to diet; iron supplementation is mainly for iron deficiency anemia, and for other causes The effect of induced anemia is not obvious, and the action period is relatively long; blood transfusion can quickly alleviate or correct anemia, which is the main measure of symptomatic treatment, but blood transfusion is more likely to cause severe transfusion reactions, increase the chance of hepatitis, syphilis, and HIV infection, and Long-term multiple blood transfusions can also cause iron overload, secondary hemochromatosis, etc. Supplementing rhEPO can accelerate the recovery of bone marrow red blood cell hematopoietic function inhibited by radiotherapy and chemotherapy, and clinical studies have proved that the application of rhEPO can significantly reduce The need for blood transfusion can increase the concentration of hemoglobin, so at present, rhEPO is mainly used to treat anemia

However, recent studies have shown that the application of rhEPO will reduce the survival time of patients, which may be related to the adverse reaction of erythropoietin - thromboembolism

Images